Cosmetic & Skin · Source-reviewed dossier
Melanotan I
Source-Reviewed Research Dossier
Melanotan I is an informal name associated with afamelanotide, a synthetic α-MSH analogue. FDA approval applies to the SCENESSE 16 mg implant for erythropoietic protoporphyria—not to tanning products, research powder or other formulations.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
- Product type
- Peptide research compound
- Catalog family
- Melanotan I
- Research category
- Cosmetic & Skin
- Catalog CAS RN
- 75921-69-6
- Catalog molecular formula
- C78H111N21O19
- Catalog molecular weight
- 1646.85 g/mol
- Catalog sequence
- Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
- Identity boundary
- The name Melanotan I is used inconsistently; equivalence to licensed afamelanotide requires exact sequence, formulation and product documentation.
- Evidence status
- Human pigmentation pharmacology and one product-specific FDA approval; catalog material is not SCENESSE
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- Afamelanotide-related α-MSH analogueCatalog-family identity
- Evidence scope
- Human pigmentation pharmacology and one product-specific FDA approval; catalog material is not SCENESSEDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
How Melanotan I is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about Melanotan I
Reported outcomes are paired with their experimental model and evidence boundary.
Pigmentation and pharmacokinetics were studied in volunteers
An early human study evaluated the synthetic melanotropin analogue now associated with afamelanotide.
Early experimental exposure does not establish safety for unapproved tanning formulations.
Read the primary studySCENESSE approval is formulation- and indication-specific
The label covers a 16 mg controlled-release implant for adults with erythropoietic protoporphyria.
It does not approve catalog Melanotan I, self-injection or cosmetic tanning.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for MT1
Product specification
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Quality documentation
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
Pigmentation and pharmacokinetics were studied in volunteers
Early experimental exposure does not establish safety for unapproved tanning formulations.
View primary recordSCENESSE approval is formulation- and indication-specific
It does not approve catalog Melanotan I, self-injection or cosmetic tanning.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Human pharmacology study
Human pigmentation and pharmacokinetics of a synthetic melanotropin
Human study. 1997. PMID 9113347.
-
02
FDA prescribing information
SCENESSE (afamelanotide) prescribing information
U.S. FDA label, revised 2024.
Melanotan I questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What is Melanotan I?
Melanotan I is an informal name associated with afamelanotide, a synthetic α-MSH analogue. FDA approval applies to the SCENESSE 16 mg implant for erythropoietic protoporphyria—not to tanning products, research powder or other formulations.
What evidence is available for Melanotan I?
Human pigmentation studies and a narrow product approval exist, but no general tanning approval follows.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should Melanotan I be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: MT1 · 10 mg × 10 vials